10-K: Vaxcyte Inks Manufacturing Deal with Lonza, Secures Key Supply Chain Component

Vaxcyte has entered into a significant manufacturing agreement with Lonza, securing a dedicated suite for production and gaining control over a crucial supply chain element.

Summary

• Vaxcyte has finalized a manufacturing agreement with Lonza for a dedicated production suite in Switzerland.
• The agreement covers pre-commercial services, suite construction, and commercial manufacturing of Vaxcytes products.
• Vaxcyte will contribute to capital expenditures for the suite build-out and pay monthly pre-commercial service fees.
• A repurposing fee of CHF 27 million will be credited back to Vaxcyte over ten years after PPQ Batches are completed.
• Post-handover, Vaxcyte will pay suite fees and FTE fees, with potential bonuses and penalties based on operational and regulatory milestones.
• Vaxcyte has also secured exclusive rights to develop and manufacture cell-free extract, a key component of its PCV franchise, from Sutro Biopharma.
• The agreement aims to provide Vaxcyte with operational flexibility, treating the suite as its own manufacturing facility.
• The agreement includes provisions for technology transfer, quality control, and regulatory compliance.
• The agreement has an initial term until December 31, 2038, with options for three five-year renewals.

Sentiment

Score: 8

Explanation: The document outlines a positive strategic move for Vaxcyte, securing manufacturing capacity and control over a key supply chain component. The terms appear favorable, with mechanisms for cost recovery and operational flexibility. The agreement is a significant step forward for the company.

Positives

• Vaxcyte secures a dedicated manufacturing suite, ensuring production capacity.
• The repurposing fee is credited back to Vaxcyte over time, reducing long-term costs.
• Vaxcyte gains operational control over the suite, enhancing flexibility.
• The acquisition of cell-free extract manufacturing rights secures a key supply chain component.
• The agreement includes a framework for collaboration and dispute resolution.
• Lonza is responsible for obtaining and maintaining the Swissmedic manufacturing license for the suite.
• Vaxcyte has the right to establish alternative suppliers, but Lonza is a preferred supplier.
• The agreement includes provisions for technology transfer assistance from Lonza.
• The agreement includes a mechanism for sharing savings from productivity improvements.
• Vaxcyte is permitted to have a certain number of employees present in the suite, with Lonza providing office space.

Negatives

• Vaxcyte is responsible for paying a repurposing fee of CHF 27 million.
• Vaxcyte is responsible for paying for all Raw Materials and consumables.
• Lonza is not responsible for analytical services performed by External Laboratories.
• Lonza is not responsible for delays arising out of Vaxcytes failure to provide Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services to Lonza.
• Lonza may adjust the Price in accordance with [***] for the previous calendar year.
• Lonza may change the Price to reflect an increase in variable costs or a material change in an environmental, safety or regulatory standard that substantially impacts Lonzas cost and ability to perform the Services.
• Vaxcyte is responsible for the direct impact, including regulatory consequences, of such directions/changes, as well as for any additional costs and expenses resulting from such changes calculated in accordance with the CMSA.

Risks

• Delays in the build-out of the suite could impact production timelines.
• Lonza is not responsible for delays arising out of Vaxcytes failure to provide Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services to Lonza.
• Lonza may adjust the Price in accordance with [***] for the previous calendar year.
• Lonza may change the Price to reflect an increase in variable costs or a material change in an environmental, safety or regulatory standard that substantially impacts Lonzas cost and ability to perform the Services.
• Vaxcyte is responsible for the direct impact, including regulatory consequences, of such directions/changes, as well as for any additional costs and expenses resulting from such changes calculated in accordance with the CMSA.
• The agreement includes termination penalties if Vaxcyte terminates for convenience.
• Force Majeure events could disrupt operations and delay production.
• Disputes between the parties could lead to delays and additional costs.
• Lonza is not responsible for delays caused by Vaxcytes failure to timely supply Vaxcyte Supplied Raw Materials or timely order Lonza Supplied Raw Materials.

Future Outlook

Vaxcyte aims to leverage the agreement for operational flexibility and to secure a reliable supply chain for its vaccine candidates. The agreement is intended to support the potential global commercialization of Vaxcytes PCV candidates.

Management Comments

• The intent of this CMSA is to provide, to the greatest extent possible, operational flexibility to Vaxcyte within the Suite after Hand Over as if the Suite was Vaxcytes own manufacturing facility.
• Vaxcyte shall be the final decision maker on all Product production scheduling and provided Lonza manufactures and delivers the Product as per the Production Scheduling Form, it shall not be responsible for stock-out situations.

Industry Context

This agreement reflects a trend in the biopharmaceutical industry towards securing dedicated manufacturing capacity and controlling key supply chain elements. It also highlights the importance of strategic partnerships for companies developing complex biologics.

Comparison to Industry Standards

• The agreement is similar to other manufacturing agreements in the biopharmaceutical industry, but includes specific provisions for Vaxcytes unique needs.
• The agreement includes a mechanism for sharing savings from productivity improvements, which is not always standard in such agreements.
• The agreement includes a mechanism for sharing savings from productivity improvements, which is not always standard in such agreements.
• The agreement includes a mechanism for sharing savings from productivity improvements, which is not always standard in such agreements.
• The agreement includes a mechanism for sharing savings from productivity improvements, which is not always standard in such agreements.

Stakeholder Impact

• Shareholders: The agreement is expected to enhance Vaxcytes long-term value by securing manufacturing capacity and supply chain control.
• Employees: The agreement may lead to new job opportunities and career growth within Vaxcyte.
• Customers: The agreement is expected to ensure a reliable supply of Vaxcytes vaccine candidates.
• Suppliers: The agreement may create new opportunities for suppliers of raw materials and equipment.
• Creditors: The agreement may improve Vaxcytes creditworthiness by securing its manufacturing capabilities.

Next Steps

• Lonza will build out the dedicated manufacturing suite.
• Vaxcyte will continue to develop its manufacturing processes.
• The parties will establish joint project teams and a steering committee.
• Vaxcyte will work towards obtaining regulatory approvals for the suite.
• Vaxcyte will determine whether to advance VAX-24 or VAX-31 to an adult Phase 3 program.

Key Dates

Keywords

Manufacturing Agreement, Lonza, Vaxcyte, Pharmaceutical Manufacturing, Biologics, Supply Chain, PCV, Vaccine Production, cGMP, Contract Manufacturing